NCT06509581

Vitamin E Supplementation for Children With Transfusion Dependent Beta Thalassemia on Different Iron Chelation Regimen

Vitamin E Supplementation for Children With Transfusion Dependent Beta Thalassemia on Different Iron Chelators

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

repeated transfusions are the mainstay of disease management in most patients with transfusion dependent beta thalassemia.iron overload predispose to oxidative stress and tissue injury. oxidative stress play important role in pathogenesis of anemia in beta thalassemia. vitamin E is often depleted in thalassemia patients.

Detailed description

oxidative stress status is very important in thalassemic patients and explains the different manifestations in thalassemic patients. vitamin E is fat soluble vitamin shown to reduce the oxidative stress in thalassemia and to reduce lipid peroxidation of red cell membranes. therefore, this study shows the safety of oral vitamin E as adjuvant therapy to three iron chelators : desferoxamine,deferiprone and deferasirox in moderately iron overloaded children and adolescents with transfusion dependent beta thalassemia and its relation to iron overload over one year.

Conditions

• Beta-Thalassemia

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	vitamin E	Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
OTHER	PLACEBO	placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )

Timeline

• Start date: 2021-07-05
• Primary completion: 2022-09-11
• Completion: 2022-10-11
• First posted: 2024-07-19
• Last updated: 2024-07-19

Locations

1 site across 1 country: Egypt